查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1308641

2030 年病毒清除市場預測 - 按方法、應用、最終用戶和地區進行的全球分析

Viral Clearance Market Forecasts to 2030 - Global Analysis By Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球病毒清除市場規模將達到 7.6464 億美元，預計到 2030 年將達到 19.3815 億美元，預測期內復合年增長率為 14.21%。

重組蛋白、糖蛋白、組織和血液衍生產品、醫療器械和單克隆抗體的開發都依賴於病毒清除過程。動物和人類細胞都可以被病毒感染，但病毒具有自我複制的能力。它還具有在細菌宿主細胞內繁殖和傳播的能力，造成損害和感染。病毒清除方法的一個關鍵組成部分是評估無風險生產產品並確保其人類使用安全的能力。原材料、下游工藝、細胞培養過程都會受到病毒感染的影響。這將有助於病毒安全實踐的發展和病毒清除流程的實施。

據 BioSpace 稱，2018 年有 386 種藥物註冊用於臨床開發，而 2008 年僅為 178 種。開發過程中的藥物數量不斷增加，對病毒清除服務的需求也隨之增加。

市場動態：

主持人：

慢性病增加

推動病毒滅活市場增長的因素包括慢性病毒感染和疾病患病率的上升以及對有效治療的需求增加。由於生命科學行業投資的增加、新藥引進的增加以及研發創新的增加，預計該市場還將增長。

抑製劑

最先進的技術帶來高成本

阻礙市場發展的是產品和技術開發成本過高。此外，緩慢的藥物開發過程以及與病毒清除相關的幾個問題（例如蛋白質交聯、蛋白質變性和蛋白質降解）限制了市場的擴張。

機會：

加強病毒安全監管

病毒安全評估是確保產品安全的重要一步。監管機構認真對待病毒安全性，並需要復雜的數據來支持它，特別是 IND 和 BLA 批准。了解監管要求、流程和流程關鍵領域對於有效的戰略規劃至關重要。藥物開發中的此類病毒安全法規正在增加對使試驗更加成功的服務的需求。

威脅

缺乏合格的專業人員

作為病毒清除服務提供商，與製藥公司、生物技術公司、醫療器械公司以及研究和學術機構競爭有才華和經驗豐富的科學家，招聘和留住高技能專業人員是我面臨的挑戰。為了在競爭中保持領先地位，公司必須提供更高的薪酬和其他激勵措施，這反過來又會影響尤其是規模較小的分析測試提供商的財務和財務績效。熟練專業人員的短缺阻礙了新技術和工藝的採用，並可能限制未來幾年的市場增長。

COVID-19 的影響：

市場受到 COVID-19 大流行的負面影響。勞動力和人員短缺、感染傳播的風險以及生物製藥和生物技術領域的生產停滯是市場面臨的挑戰。然而，2021年，市場增長急劇加速。這種增長歸因於臨床試驗的增加。為了開發針對SARS-CoV-2病毒的疫苗和藥物，許多製藥和生物製藥公司增加了研發和製造流程。此外，自 COVID-19 爆發以來，與製藥公司和學術機構就 COVID-19 疫苗開發建立了許多新的全球夥伴關係和合作。

在預測期內，重組蛋白行業預計將是最大的：

預計重組蛋白領域將在預測期內佔據最大的市場份額。影響該領域增長的主要因素之一是對治療牛皮癬、多發性硬化症、風濕病和炎症性腸病等炎症性疾病的生物製藥的需求不斷增長。隨著重組蛋白的引入，生物製藥的生產和開發已經徹底改變。隨著許多由重組蛋白製成的生物製劑和疫苗正在研發中並預計將獲得 FDA 的批准，重組藥物的數量預計將增長。因此，考慮到上述所有因素，預計市場將會增長。

合同研究組織部門預計在預測期內復合年增長率最高：

隨著主要市場進入者增加對各種研究機構的投資以改進產品，預計未來幾年合同研究機構市場將出現強勁增長。合同研究機構大力投資藥物發現基礎設施的能力以及初創企業、學術機構、製藥公司和小型生物技術公司等組織越來越多地將藥物發現服務外包給 CRO 是推動全球需求的一個關鍵因素。美國病毒清除市場的非凡增長。

佔比最大的地區：

預計北美將在整個預測期內主導病毒清除市場。重要參與者的存在及其對尖端醫療技術的進步是獲得最大份額的主要因素。市場擴張的主要驅動力是重組蛋白和疫苗產量的增加以及保護它們免受病毒和風險影響的需要。此外，人們對使用生物製藥的好處的認識不斷增強，增加了對病毒清除相關服務的需求。此外，由於美國各地藥品資金的增加，市場正在擴大。

複合年增長率最高的地區：

由於政府對醫學研究的投資增加和醫療保健成本飆升，以及中國、日本和印度等國家細胞培養物污染和 CRO 存在的風險增加，預計亞太地區在預測期內將出現顯著增長. 增加。據世界衛生組織統計，超過1500萬年齡在35歲至69歲之間的人死於慢性病，其中發達國家和發展中國家均佔過早死亡的85%。此外，還有許多臨床研究服務，尤其是在中國，預計將刺激未來市場的擴張。

重大發展

2022 年 9 月，Merck將開設病毒清除 (VC) 實驗室，作為其耗資 2,900 萬歐元新建的中國生物製品檢測中心 1 號樓的一部分。

2022 年 4 月，研究員 (PRO) Abzena 宣佈在其位於加利福尼亞州聖地亞哥的生物製劑工藝開發和製造中心附近開設一個生物製劑測試實驗室。該設施將為合作夥伴提供基於細胞和 PCR 安全檢測、病毒清除研究的機會，以支持 IND、IMPD、BLA 和 MAA 提交。

2022年4月，WuXi Biologics榮獲亞太生物工藝卓越獎（ABEA）第二屆病毒清除和安全性生物工藝卓越獎。

報告內容

  • 區域和國家層面的市場份額評估
  • 對新進入者的戰略建議
  • 涵蓋 2021、2022、2023、2026 和 2030 年的市場數據
  • 市場趨勢
  • 根據市場預測提出關鍵業務領域的戰略建議
  • 競爭格局映射關鍵共同趨勢
  • 公司概況，包括詳細戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制服務：

訂閱此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要公司的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家的市場估計/預測/複合年增長率（注：通過可行性檢查）
  • 競爭標桿
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

目錄

第一章內容提要

第二章前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第三章市場趨勢分析

  • 促進者
  • 抑製劑
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5 全球病毒清除市場（按方法）

  • 病毒清除
    • 色譜法
    • 納濾
    • 沉澱法
  • 病毒滅活
    • 低pH值
    • 溶劑清洗法
    • 加熱滅菌
    • 其他病毒滅活方法
  • 病毒檢測方法

6. 全球病毒清除市場（按應用）

  • 重組蛋白
  • 血液和血液製品
  • 細胞和基因治療產品
  • 疫苗接種
  • 其他用途

7. 全球病毒清除市場（按最終用戶）

  • 製藥和生物技術公司
  • 學術研究所
  • 合同研究所
  • 其他最終用戶

8. 全球病毒清除市場（按地區）

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲

第九章 主要進展

  • 協議、夥伴關係、協會和合資企業
  • 收購與合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第十章公司簡介

  • Avance Biosciences Inc.
  • BioReliance Corporation
  • Bioscience Laboratories
  • BSL Bioservice Scientific Laboratories GmbH
  • Charles River Laboratories, Inc.
  • Clean Cells Inc.
  • Cytovance Biologics Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Life Sciences
  • Kedrion Biopharma Inc.
  • Labor Dr. Merk & Kollegen GmbH
  • Lonza Group AG
  • Merck KGaA
  • Nelson Laboratories LLC
  • Novartis AG
  • Sartorius AG
  • Sigma-Aldrich Corporation
  • Syngene International Limited
  • Texcell, Inc.
  • Vironova AB
  • ViruSure GmbH
  • WuXi AppTec
Product Code: SMRC23341

According to Stratistics MRC, the Global Viral Clearance Market is accounted for $764.64 million in 2023 and is expected to reach $1938.15 million by 2030 growing at a CAGR of 14.21% during the forecast period. The development of recombinant proteins, glycoproteins, tissue- and blood-derived products, medical devices, and monoclonal antibodies all depend on the viral clearance process. Animal or human cells can become infected by viruses, which have the capacity to multiply on their own. Additionally, they have the power to multiply and spread within the host cell of bacteria, causing damage and infection. An important component of the viral clearance method is the evaluation of the capacity to produce a product without risk and guarantee the product's safety for human use. Raw materials, downstream processing, and cell culture processes are all impacted by viral infections. This would contribute to the development of viral safety practices and the implementation of the virus clearance process.

According to BioSpace, in 2018, 386 drugs were registered for clinical development, observing a significant growth from 2008, when the number of drugs was only 178. The increase in the number of drugs in the development process has increased viral clearing services' demand.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

Some of the factors propelling the growth of the viral inactivation market include the rising prevalence of chronic viral infections and diseases and the rising demand for effective treatment methods. Additionally, the market is expected to grow as a result of rising investment in the life sciences industry, the introduction of more new drugs, and increased R&D innovation.

Restraint:

High costs incurred by cutting-edge technologies

The market expansion is being hampered by high development costs for goods and technology. Additionally, the lengthy drug development process and some issues related to virus clearance, such as protein crosslinking, protein denaturation, and protein degradation, are restricting the market's expansion.

Opportunity:

Increasing viral safety regulations

The evaluation of viral safety is an important step in ensuring the safety of products. Regulatory agencies place a lot of emphasis on viral safety and demand high-caliber data to support it, particularly for IND and BLA approvals. For effective strategic planning, it is crucial to be knowledgeable about the regulatory requirements, the process, and the key areas of the process. These viral safety regulations during the development of pharmaceutical products have increased the demand for services to conduct studies more successfully.

Threat:

Scarcity of qualified specialists

Virus removal service providers face challenges in attracting and retaining highly skilled professionals as they compete for qualified and experienced scientists with pharmaceutical companies, biotechnology companies, medical device companies, and research and academic institutions. Companies have to offer higher compensation and other incentives to compete, which affects the finances and performance of players, especially smaller analytics test providers. This scarcity of skilled professionals may hinder the adoption of new technologies and processes, limiting the growth of the market in the coming years.

COVID-19 Impact:

The market was negatively impacted by the COVID-19 pandemic. The market was challenged by a lack of workers and staff, a risk of infection spread, and a slowdown in manufacturing in the biopharmaceutical and biotech sectors. However, the market witnessed a sharp acceleration in growth in 2021. This growth was attributed to an increase in clinical trials. To develop vaccines and medications against the SARS-CoV-2 virus, many pharmaceutical and biopharmaceutical companies increased their R&D and manufacturing processes. Additionally, following the COVID-19 outbreak, there have been numerous new global partnerships and collaborations with pharmaceutical companies and academic institutions for the development of COVID-19 vaccines.

The recombinant proteins segment is expected to be the largest during the forecast period:

During the forecast period, the recombinant proteins segment is anticipated to hold the largest market share. One of the main factors influencing the segment's growth is the rising demand for biopharmaceuticals for managing inflammatory diseases like psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases. The production and development of biotherapeutics have been completely transformed by the introduction of recombinant proteins. As numerous biologics and vaccines made of recombinant proteins are currently in the pipeline and are anticipated to receive FDA approval, it is anticipated that the number of recombinant drugs will increase. The market is therefore anticipated to grow in light of all the aforementioned factors.

The contract research organizations segment is expected to have the highest CAGR during the forecast period:

Due to growing investments by major market players in various research organizations to improve their products, the contract research organizations segment is anticipated to experience strong market growth in the upcoming years. The ability of contract research organizations to make significant investments in drug discovery infrastructure and an increase in the outsourcing of drug discovery services to CROs by organizations like start-ups, academic institutions, pharmaceutical companies, and small biotechnology companies are the main factors behind their extraordinary growth in the global viral clearance market.

Region with largest share:

Throughout the forecast period, North America is anticipated to dominate the viral clearance market. The presence of important players and their use of cutting-edge medical technologies to advance are primarily responsible for the largest share. The primary driver of market expansion is the rise in the production of recombinant proteins and vaccines, as well as the requirement to keep them virus- and risk-free. Additionally, the population is becoming more aware of the benefits of using biopharmaceuticals, which is driving up demand for services related to viral clearance. Furthermore, the market is expanding as a result of increased funding for pharmaceuticals across the United States.

Region with highest CAGR:

Due to rising government investments in medical research and rising healthcare costs, Asia Pacific is expected to grow significantly during the forecast period, which will increase the risk of cell culture contamination and the presence of CROs in nations like China, Japan, and India. According to statistics from the WHO, more than 15 million people between the ages of 35 and 69 die from chronic diseases, and both developed and developing nations account for 85% of premature deaths. Additionally, a large number of clinical research services, particularly in China, are anticipated to fuel market expansion in the upcoming years.

Key players in the market

Some of the key players profiled in the Viral Clearance Market include Avance Biosciences Inc., BioReliance Corporation, Bioscience Laboratories, BSL Bioservice Scientific Laboratories GmbH, Charles River Laboratories, Inc., Clean Cells Inc., Cytovance Biologics Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare Life Sciences, Kedrion Biopharma Inc., Labor Dr. Merk & Kollegen GmbH, Lonza Group AG, Merck KGaA, Nelson Laboratories LLC, Novartis AG, Sartorius AG, Sigma-Aldrich Corporation, Syngene International Limited, Texcell, Inc., Vironova AB, ViruSure GmbH and WuXi AppTec.

Key Developments:

In September 2022, Merck opened a viral clearance (VC) laboratory as part of the first building phase of its new EUR 29 million China Biologics Testing Center.

In April 2022, Abzena, a partner research organization (PRO), announced the opening of a biologics testing laboratory situated near the company's biologics process development and manufacturing hub in San Diego, California. The facility will give partners access to cell-based and PCR safety assays; and viral clearance studies to support their IND, IMPD, BLA, and MAA applications.

In April 2022, WuXi Biologics awarded the bioprocessing excellence in viral clearance and safety accolade for the second time at the Asia Pacific Bioprocessing Excellence Awards (ABEA) event.

Methods Covered:

  • Viral Removal
  • Viral Inactivation
  • Viral Detection Method

Application Covered:

  • Recombinant Proteins
  • Blood and Blood Products
  • Cellular and Gene Therapy Products
  • Vaccines
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Clearance Market, By Method

  • 5.1 Introduction
  • 5.2 Viral Removal
    • 5.2.1 Chromatography
    • 5.2.2 Nanofiltration
    • 5.2.3 Precipitation
  • 5.3 Viral Inactivation
    • 5.3.1 Low pH
    • 5.3.2 Solvent Detergent Method
    • 5.3.3 Heat Pasteurization
    • 5.3.4 Other Viral Inactivation Methods
  • 5.4 Viral Detection Method

6 Global Viral Clearance Market, By Application

  • 6.1 Introduction
  • 6.2 Recombinant Proteins
  • 6.3 Blood and Blood Products
  • 6.4 Cellular and Gene Therapy Products
  • 6.5 Vaccines
  • 6.6 Other Applications

7 Global Viral Clearance Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical and Biotechnology Companies
  • 7.3 Academic Research Institutes
  • 7.4 Contract Research Organizations
  • 7.5 Other End Users

8 Global Viral Clearance Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Avance Biosciences Inc.
  • 10.2 BioReliance Corporation
  • 10.3 Bioscience Laboratories
  • 10.4 BSL Bioservice Scientific Laboratories GmbH
  • 10.5 Charles River Laboratories, Inc.
  • 10.6 Clean Cells Inc.
  • 10.7 Cytovance Biologics Inc.
  • 10.8 Eurofins Scientific
  • 10.9 F. Hoffmann-La Roche Ltd.
  • 10.10 GE Healthcare Life Sciences
  • 10.11 Kedrion Biopharma Inc.
  • 10.12 Labor Dr. Merk & Kollegen GmbH
  • 10.13 Lonza Group AG
  • 10.14 Merck KGaA
  • 10.15 Nelson Laboratories LLC
  • 10.16 Novartis AG
  • 10.17 Sartorius AG
  • 10.18 Sigma-Aldrich Corporation
  • 10.19 Syngene International Limited
  • 10.20 Texcell, Inc.
  • 10.21 Vironova AB
  • 10.22 ViruSure GmbH
  • 10.23 WuXi AppTec

List of Tables

  • Table 1 Global Viral Clearance Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 3 Global Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 4 Global Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 5 Global Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 6 Global Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 7 Global Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 8 Global Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 9 Global Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 10 Global Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 11 Global Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 12 Global Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 13 Global Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 15 Global Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 16 Global Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 17 Global Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 18 Global Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 19 Global Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 21 Global Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 22 Global Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 23 Global Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 26 North America Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 27 North America Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 28 North America Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 29 North America Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 30 North America Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 31 North America Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 32 North America Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 33 North America Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 34 North America Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 35 North America Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 36 North America Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 38 North America Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 39 North America Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 40 North America Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 41 North America Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 42 North America Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 44 North America Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 45 North America Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 46 North America Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 49 Europe Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 50 Europe Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 51 Europe Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 52 Europe Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 53 Europe Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 54 Europe Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 55 Europe Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 56 Europe Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 57 Europe Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 58 Europe Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 59 Europe Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 60 Europe Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 61 Europe Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 62 Europe Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 63 Europe Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 64 Europe Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 65 Europe Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 67 Europe Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 68 Europe Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 69 Europe Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 72 Asia Pacific Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 73 Asia Pacific Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 74 Asia Pacific Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 75 Asia Pacific Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 76 Asia Pacific Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 77 Asia Pacific Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 78 Asia Pacific Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 79 Asia Pacific Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 80 Asia Pacific Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 81 Asia Pacific Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 82 Asia Pacific Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 83 Asia Pacific Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 84 Asia Pacific Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 85 Asia Pacific Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 86 Asia Pacific Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 87 Asia Pacific Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 88 Asia Pacific Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 90 Asia Pacific Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 91 Asia Pacific Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 92 Asia Pacific Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 95 South America Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 96 South America Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 97 South America Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 98 South America Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 99 South America Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 100 South America Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 101 South America Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 102 South America Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 103 South America Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 104 South America Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 105 South America Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 106 South America Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 107 South America Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 108 South America Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 109 South America Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 110 South America Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 South America Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 113 South America Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 114 South America Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 115 South America Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 118 Middle East & Africa Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 119 Middle East & Africa Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 120 Middle East & Africa Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 121 Middle East & Africa Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 122 Middle East & Africa Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 123 Middle East & Africa Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 124 Middle East & Africa Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 125 Middle East & Africa Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 126 Middle East & Africa Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 127 Middle East & Africa Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 128 Middle East & Africa Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 129 Middle East & Africa Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 130 Middle East & Africa Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 131 Middle East & Africa Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 132 Middle East & Africa Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 133 Middle East & Africa Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 134 Middle East & Africa Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 136 Middle East & Africa Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 137 Middle East & Africa Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 138 Middle East & Africa Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)